Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements.
The pharmaceutical probiotic VSL#3 (300 billion cfu/g lactic acid bacteria & bifidobacteria) was inoculated into human ileostomy effluent (HIE) to assess its behaviour vs the ileo-caecal tract. Separately, yogurt bacteria (yog) and bifidobacteria (Bif) present in VSL#3 were also inoculated into HIE. During 37 degrees C incubation (anaerobic condition) at zero, six and 24 hours, both cell growth in control HIE and indigenous Bif growth in HIE+yog were observed. Cells remained viable and metabolically active as shown by the increase in L(+) lactic acid in HIE+VSL#3 and HIE+yog and the pH decreased (approx. 5.5 compared with the 6.2 of control HIE). Total SCFA Short Chain Fatty Acids decreased in HIE+yog and HIE+VSL#3 at 6h and in all cultures at 24h; butyric acid decreased in HIE+Bif and HIE+VSL#3. Generally in vivo the bacteria remain in the ileo-caecal tract no longer than six h, therefore VSL#3 bacteria seem able to pass this barrier viably, colonizing the large bowel.
Bianchi-Salvadori
B
B
Centro Sperimentale del Latte SpA, Zelo Buon Persico, Italy.
Vesely
R
R
Ferrari
A
A
Canzi
E
E
Casiraghi
C
C
Brighenti
F
F
D000328:Adult; D001644:Bifidobacterium / Q000254:growth & development; D001647:Bile Acids and Salts / Q000032:analysis; D003093:Colitis, Ulcerative / Q000382:microbiology / Q000601:surgery; D015169:Colony Count, Microbial; D005232:Fatty Acids, Volatile / Q000032:analysis; D005285:Fermentation; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007081:Ileostomy; D007082:Ileum / Q000201:enzymology / Q000378:metabolism / Q000382:microbiology*; D019344:Lactic Acid / Q000378:metabolism; D007778:Lactobacillus / Q000254:growth & development; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000378:metabolism / Q000494:pharmacology*
D001647:Bile Acids and Salts; D005232:Fatty Acids, Volatile; D019344:Lactic Acid